top of page
.png)
TAGS
Hepatology
HCV Micro-elimination in Hong Kong, Insights from AASLD the Liver Meeting
"The current progress of HCV elimination in Hong Kong is a bit left behind, yet latest strategies and policy have loosen access criteria for Direct-Acting Antiviral (DAA) therapies, making it possible for Hong Kong to catch up with other countr...
Dec 28, 2020
Treatment on Antibiotic Resistance in Helicobacter Pylori
Treatment on Antibiotic Resistance in Helicobacter Pylori Helicobacter pylori (H. pylori) is a bacterium that infects more than half of the worldwide population. H. pylori infection is the main cause of chronic gastritis and the etiological agent fo...
Mar 16, 2021
HCV Micro-elimination in Hong Kong, Insights from AASLD the Liver Meeting
“The current progress of HCV elimination in Hong Kong is a bit left behind, yet latest strategies and policy have loosen access criteria for Direct-Acting Antiviral (DAA) therapies, making it possible for Hong Kong to catch up with other count...
Mar 16, 2021
The 9th Annual Scientific Meeting of the Hong Kong Society of Hepatobiliary and Pancreatic Surgery
The 9 th Annual Scientific Meeting of the Hong Kong Society of Hepatobiliary and Pancreatic Surgery Liver cancer is one of the leading causes of cancer-related death globally. The prognosis of liver cancers is usually poor, and predicting life expec...
Jun 21, 2021
POEMS Syndrome – A Rare and Challenging Disorder
The POEMS syndrome is a rare plasma cell disorder involving pathological changes of polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes. The diagnostic and therapeutic management of the disease is clinically challenging. Given ...
Jun 13, 2023
Switching for a Better Renal Outcome in the Management of Chronic Hepatitis B
Attention deficit hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders in children, with an estimated global prevalence of 5–7% in school-aged children. It is characterised by hyperactivity and impulsivity with ...
Aug 11, 2023
Hepatocellular Carcinoma: A Disease with Ethnic & Geographic Differences
Hepatocellular carcinoma (HCC) is ranked as the sixth most common cancer worldwide and its incidence has been progressively increasing. HCC is also the third most common cause of cancer-related death, with a 5-year survival rate of just 3% 1 . Inter...
Oct 22, 2024
Are We Doing Our Best to Reduce the Risk of HCC in HBV Patients?
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death worldwide. Essentially, persistent hepatitis B virus (HBV) infection is one of the most important risk factors for HCC1. Thus, targeted strategies to mitigate HBV ...
Feb 17, 2025
Advancing HCV Elimination in Marginalised Communities: Strategies and Challenges
The availability of safe and effective oral direct-acting antivirals (DAAs) has paved the path to eliminating hepatitis C (HCV) infection. Accordingly, the World Health Organisation (WHO) addressed a global target in 2016 for the elimination of HCV ...
Apr 11, 2025
Mitigating HCC Risk through Managing HBV Infection – The Insights from the Updated EASL Guidelines
Chronic hepatitis B (CHB) is one of the leading causes of hepatocellular carcinoma (HCC), cirrhotic complications and liver-related death worldwide. Therefore, controlling chronic hepatitis B virus (HBV) infection is crucial for reducing the risk of...
Aug 14, 2025
ENTECAVIR TEVA
ENTECAVIR TEVA ® (entecavir) TEVA HK Reg. No. HK-68822 (27 Aug, 2025) Composition: 2 • Available in the dosage form of 0.5 mg film-coated tablets Indication: 2 • Indicated for chronic hepatitis B virus (HBV) infection in adults. This m...
Oct 24, 2025
HEPWIN®
HEPWIN ® (entecavir) VIATRIS HK Reg. No. HK-68889 (28 Oct, 2025) Composition: 4 • Each film-coated tablet contains entecavir monohydrate equivalent to 0.5 mg entecavir Indication: 4 • Indicated for the treatment of chronic hepatitis B ...
Dec 19, 2025
POPULAR STORY
A Silent Killer No More: How New Discoveries Are Changing Pancreatic Cancer Outcomes
Dr. Feng Xue
Hope in Motion: Clinical Progress and Social Support for Parkinson’s
Andrew Chan
Uncovering the Tricks of the Silent Thief of Sight
Dr. Roy Lau
Dec 19, 2024
What’s New in Coronary Artery Disease?
Dr. Roy Lau
Aug 20, 2024
Challenges and Strategies for Managing CHB Patients with Co-morbidities
Dr. Roy Lau
Jun 21, 2024
Decoding the Paradox on Impact of Obesity on Cognitive Functioning
Dr. Roy Lau
Jun 20, 2024
bottom of page